Clinical Trial Update: A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ONM-100 as an intraoperative fluorescence imaging agent for cancer detection has completed enrollment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Prostate Cancer
• Urothelial Carcinoma

Drugs mentioned

• ONM-100

Snippet

Sponsor: OncoNano Medicine, Inc. | Conditions: Breast Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-07-07